Rate control in atrial fibrillation using Landiolol is safe in critically ill Covid-19 patients

Landiolol infusion was started at 0.2 µg/kg/min and dosage reached 3.9 [1.6–7.0] µg/kg/min at 24 h. Overall heart rate reduction was 23% (115 [108–117] vs 150 [138–160] bpm; p 

Saved in:
Bibliographic Details
Published in:Critical care (London, England) England), 2021-01, Vol.25 (1), p.33-3, Article 33
Main Authors: Hariri, Geoffroy, Urbina, Tomas, Mazerand, Sandie, Bige, Naike, Baudel, Jean-Luc, Ait-Oufella, Hafid
Format: Article
Language:English
Subjects:
Aged
Atrial fibrillation
Atrial Fibrillation - drug therapy
Beta blockers
Cardiac arrhythmia
Catecholamines
Coronaviruses
COVID-19
COVID-19 - drug therapy
Critical care
Critical Illness
Critically ill
Drug dosages
Drug therapy
Female
Heart rate
Heart Rate - drug effects
Hemodynamics
Hospitalization
Humans
Infections
Intensive care
Intensive Care Units
Life Sciences
Male
Morpholines - adverse effects
Morpholines - pharmacology
Morpholines - therapeutic use
Patient Safety
Patients
Prospective Studies
Research Letter
Sepsis
Severe acute respiratory syndrome coronavirus 2
Sympathomimetic agents
Treatment Outcome
Urea - adverse effects
Urea - analogs & derivatives
Urea - pharmacology
Urea - therapeutic use
Ventilators
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Landiolol infusion was started at 0.2 µg/kg/min and dosage reached 3.9 [1.6–7.0] µg/kg/min at 24 h. Overall heart rate reduction was 23% (115 [108–117] vs 150 [138–160] bpm; p 
ISSN:1364-8535
1466-609X
1364-8535
1366-609X
DOI:10.1186/s13054-021-03470-3